Association of the combination of stemness gene amplifications and copy number aberrations of WNT-signaling genes in breast tumors with metastasis

Автор: Litviakov Nikolai V., Ibragimova Marina K., Tsyganov Matvey M., Deriusheva Irina V., Pevsner Alina M., Garbukov Eugeniy Yu., Doroshenko Artem V., Slonimskaya Elena M.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Лабораторные и экспериментальные исследования

Статья в выпуске: 3 т.19, 2020 года.

Бесплатный доступ

We studied the association between the presence of 2 or more stemness gene amplifications as well as copy number aberrations (CNAs) of WNT signaling genes in residual breast tumor and metastasis. WNT pathway genes associated with metastasis were identified. Material and Methods. The study included 30 patients with breast cancer, who had 2 or more stemness gene amplifications in the residual tumor after neoadjuvant chemotherapy. Fifteen of the thirty patients developed hematogenous metastases; they constituted a group with metastases, the remaining 15 patients entered the second group without metastases. The tumor DNA was examined using a CytoScanHD Array microarray (Affymetrix, USA). Results. By subtracting amplification and deletion frequencies in 852 cytobands between groups with metastases and without metastases, 21 cytobands were identified with the largest difference in deletion and amplification frequencies. They contain 19/150 of WNT genes (12 activators: SKP1, WNT8A, MAPK9, CCND3, FZD9, WNT8B, CCND1, PLCB2, PRKCB, FZD2, WNT3, WNT9B and 7 negative regulators: GSK3B, APC, CSNK2B, SFRP5, BTRC, TCF7L2, CSNK2A2). A point system was developed: when amplifying WNT-signaling activators or deletion of negative regulators, one point was added to the total score, and vice versa when deleting WNT-signaling activators or amplification of negative regulators, one point was taken from the total amount. it was shown that 93% (14/15) of patients with metastases had a total score higher than 0, while 93% (14/15) of patients without metastases had a total score of zero or less than zero. The differences between the groups were statistically significant according to the two-sided Fisher test with a high level of confidence probability (p=0.000003) and the log-rank test (p=0.00004) when assessing non-metastatic survival by the Kaplan-Mayer method. Conclusion Nineteen WNT signaling genes were identified. Copy number aberrations of these genes in combination with stemness gene amplifications in residual tumors were associated with metastasis. A new highly effective prognostic factor for breast cancer was identified.

Еще

Breast cancer, wnt-pathway, metastasis, copy number aberration, residual tumor, wnt-сигналинг

Короткий адрес: https://sciup.org/140254355

IDR: 140254355   |   DOI: 10.21294/1814-4861-2020-19-3-78-88

Список литературы Association of the combination of stemness gene amplifications and copy number aberrations of WNT-signaling genes in breast tumors with metastasis

  • Litviakov N., Ibragimova M., TsyganovM., Kazantseva P., Deryu-sheva I., Pevzner A., Doroshenko A., Garbukov E., Tarabanovskaya N., Slonimskaya E. Amplifications of stemness genes and the capacity of breast tumors for metastasis. Oncotarget. 2020; 11: 1988-2001. doi: 10.18632/ oncotarget.27608.
  • Milanovic M, Fan D.N.Y., Belenki D., Däbritz J.H.M., Zhao Z, Yu Y., Dörr J.R., Dimitrova L., Lenze D., Monteiro Barbosa I.A., Mendoza-Parra M.A., Kanashova T., Metzner M., PardonK., ReimannM., Trumpp A., Dörken B., Zuber J., Gronemeyer H., Hummel M., Dittmar G., Lee S., Schmitt C.A. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018 Jan 4; 553(7686): 96-100. doi: 10.1038/nature25167.
  • Zhan T., RindtorffN., BoutrosM. Wnt signaling in cancer. Oncogene. 2017 Mar; 36(11): 1461-1473. doi: 10.1038/onc.2016.304.
  • Acebron S.P., Karaulanov E., Berger B.S., Huang Y.-L., Niehrs C. Mitotic wnt signaling promotes protein stabilization and regulates cell size. Molecular cell. 2014; 54(4): 663-74. doi.org/10.1016/j.mol-cel.2014.04.014
  • KaveriD., KastnerP., DembeleD., Nerlov C., Chan S., KirstetterP. p-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood. 2013 Aug 1; 122(5): 694-704. doi: 10.1182/blood-2012-12-471904.
  • WolffA.C., HammondM.E, HicksD.G., Dowsett M., McShaneL.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., SpearsP.A., Vance G.H., Viale G., Hayes D.F.; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1; 31(31): 3997-4013. doi: 10.1200/JC0.2013.50.9984.
  • Hayward J.L., CarboneP.P., Heusen J.C., Kumaoka S., Segaloff A., Rubens R.D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar; 35(3): 292-8. doi: 10.1038/bjc.1977.42.
  • Dodson A., Okonji D., Assersohn L., Rigg A., Sheri A., Turner N., Smith I., Parton M., Dowsett M. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. Breast Cancer Research and Treatment. 2018; 168(1): 249-58. doi: 10.1007/s10549-017-4514-z.
  • Tudoran O., Soritau O., Balacescu L., Visan S., Barbos O., Cojoc-neanu-Petric R., Balacescu O., Berindan-Neagoe I. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem. 2015 Nov; 409(1-2): 163-76. doi: 10.1007/s11010-015-2522-z.
  • Roy P.G., Thompson A.M. Cyclin D1 and breast cancer. Breast. 2006 Dec; 15(6): 718-27. doi: 10.1016/j.breast.2006.02.005.
  • Adorno-Cruz V., Hoffmann A.D., Liu X., Dashzeveg N.K., Taftaf R., Wray B., Liu H. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes & Diseases. 2020. doi: doi: 10.1016/j.gendis.2020.01.015.
  • Koo K.H., Kwon H. MicroRNA miR-4779 suppresses tumor growth by inducing apoptosis and cell cycle arrest through direct targeting of PAK2 and CCND3. Cell Death Dis. 2018; 9(2): 77. doi: 10.1038/ s41419-017-0100-x.
  • Liu Y.Q., Wang X.L., Cheng X., Lu Y.Z., Wang G.Z., Li X.C., Zhang J., Wen Z.S., Huang Z.L., Gao Q.L., Yang L.N., Cheng Y.X., Tao S.C., Liu J., Zhou G.B. Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitors. Oncotarget. 2015; 6(33): 34953-67. doi: 10.18632/oncotarget.5547.
  • D'ArcyB.M., SwingleM.R., Papke C.M., AbneyK.A., BouskaE.S., Prakash A., Honkanen R.E. The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C. Mol Cancer Ther. 2019 Mar; 18(3): 556-566. doi: 10.1158/1535-7163.MCT-17-1143.
  • Wu Y., Tran T., Dwabe S., Sarkissyan M., Kim J., Nava M., Clayton S., Pietras R., Farias-Eisner R., Vadgama J.V. A83-01 inhibits TGF-ß-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3): 449-460. doi: 10.1007/s10549-017-4211-y.
  • Ding L.C., Huang X. Y., Zheng F.F., Xie J., She L., Feng Y., Su B.H., ZhengD.L., Lu Y.G. FZD2 inhibits the cell growth and migration of salivary adenoid cystic carcinomas. Oncol Rep. 2016; 35(2): 1006-12. doi: 10.3892/or.2015.3811.
  • Zhang Y., Du J., Zheng J., Liu J., Xu R., Shen T., Zhu Y., Chang J., Wang H., Zhang Z., Meng F., Wang Y., Chen Y, Xu Y, Gu L. EGF-reduced Wnt5a transcription induces epithelial-mesenchymal transition via Arf6-ERK signaling in gastric cancer cells. Oncotarget. 2015 Mar 30; 6(9): 7244-61. doi: 10.18632/oncotarget.3133.
  • Yamamoto H., Oue N., Sato A., Hasegawa Y., Yamamoto H., Matsubara A., Yasui W., Kikuchi A. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene. 2010 Apr 8; 29(14): 2036-46. doi: 10.1038/onc.2009.496.
  • Gujral T.S., Chan M., Peshkin L., Sorger P.K., Kirschner M.W., MacBeath G. A noncanonical Frizzled2 pathway regulates epithelialmesenchymal transition and metastasis. Cell. 2014; 159(4): 844-56. doi: 10.1016/j.cell.2014.10.032.
  • Wong A.L.A., Tan K.T., Sundar R, Ow S., Pang A., Yap H-L., Chan C-W., HartmanM., IauP., Buhari S.A. Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC). J Clin Oncol. 2017; 35: 15_suppl. doi: 10.1200/JC0.2017.35.15_suppl.e12122.
  • Shi Q, Liu H, Han P., Li C, Wang Y, Wu W., Zhu D., Amos C.I., Fang S., Lee J.E., Han J., Wei Q. Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol. 2017; 137(8): 1749-56. doi: 10.1016/j.jid.2017.04.023.
  • Wu H., Lu X.X., Wang J.R., Yang T.Y., Li X.M., He X.S., Li Y., Ye W.L., Wu Y., Gan W.J., Guo P.D., Li J.M. TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/ß-catenin degradation and is targeted for GSK3B/GSK3ß-mediated phosphorylation and degradation. Autophagy. 2019 Sep; 15(9): 1506-22. doi: 10.1080/15548627.2019.1586250.
  • Chen I.C., Hsiao L.P., Huang I.W., Yu H.C., Yeh L.C., Lin C.H., Wei-Wu Chen T., Cheng A.L., Lu Y.S. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. Sci Rep. 2017; 7(1): 9842. doi: 10.1038/ s41598-017-10555-z.
  • Zhou W., Tian M., Hu J., Li L., He Y. SFRP5 as a prognostic biomarker for patients with pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 2016; 9(3): 3442-3447.
  • VeeckJ., Geisler C., NoetzelE., AlkayaS., Hartmann A., KnüchelR., Dahl E. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis. 2008 May; 29(5): 991-8. doi: 10.1093/carcin/ bgn076.
  • Van Klompenberg M.K., Leyden E., Arnason A.H., Zhang J.T., Stefanski C.D., Prosperi J.R. APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. Oncotarget. 2017; 8(61): 102868-79. doi: 10.18632/oncotarget.22263.
  • Stefanski C.D., Keffler K., McClintock S., Milac L., Prosperi J.R. APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia. 2019; 21(12): 1143-50. doi.org/10.1016/j. neo.2019.09.002.
  • Onder T.T., Kara N., Cherry A., Sinha A.U., Zhu N., Bernt K.M., Cahan P., Marcarci B.O., Unternaehrer J., Gupta P.B., Lander E.S., Armstrong S.A., Daley G.Q. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 4; 483(7391): 598-602. doi: 10.1038/nature10953.
Еще
Статья научная